India ups direct foreign investment cap in drug companies to 74% from 49%
23 June 2016
Prospects for higher foreign portfolio and overseas company investment in Indian drug firms brightened as the government moved to raise the direct shareholding cap to 74%.
China pilot eyes easier marketing authorization
23 June 2016
A pilot program to widen eligibility for drug marketing authorization approval by the China FDA will help small and innovative companies get drugs to market at a lower cost.
U.K. biotech holds its breath as voters decide whether to split from EU
22 June 2016
As U.K. voters head to the polls on Thursday for the EU referendum, uncertainty for life sciences looms large. FierceBiotech talks to biotech execs, regulators and trade groups to assess the mood ahead of Thursday’s vote.
Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV
22 June 2016
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, tMarinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it has dosed the first subject in its Phase 1 clinical trial of ganaxolone IV, an intravenous (IV) formulation of Marinus' CNS-selective GABAA modulator, for the treatment of status epilepticus (SE).
Americans spent $30.2 billion out-of-pocket on complementary health approaches
22 June 2016
Americans spent $30.2 billion — $28.3 billion for adults and $1.9 billion for children — out-of-pocket on complementary health approaches, according to a nationwide survey. These approaches include a group of diverse medical and health care systems, practices, and products such as herbal supplements, meditation, chiropractic, and yoga. This amount represents 9.2 percent of all out-of-pocket spending by Americans on health care and 1.1 percent of total health care spending.
Pharma rep pay scrapes the bottom of the medical sales barrel
22 June 2016
Pharma reps, we have some good news and some bad news. The good: Starting salaries in your field are among the top 10 for entry-level jobs this year. The not so good: Once again, your pay ranks lowest among U.S. medical sales folks.
Where the money is: The top 100(+) VCs investing in U.S. biotechs
21 June 2016
2015 proved to be the biggest year on record for venture investing in U.S. biotechs. A total of $7.7 billion flowed into a range of startups, some clustered in Boston/Cambridge and San Francisco, but with quite a large amount finding its way to drug developers off the beaten biotech path.
IBM signs up to support genomic research into pediatric conditions
21 June 2016
IBM ($IBM) has entered into a 5-year collaboration with the University of Calgary. The alliance will see IBM install computing and storage infrastructure at the university to support its research into the genetics of conditions including autism.
Most U.S. payers are eyeing outcomes-based drug pricing: Report
21 June 2016
Pharma may have pulled off only a few outcomes-based pricing deals with payers, but companies are likely to add more to that list soon--many more, if payers have their way.
Improving Health Through Medication Access
20 June 2016
In January 2010, Dominique Dormeville watched as her parents’ home country of Haiti suffered in the aftermath of a devastating earthquake that affected many of her friends and relatives. In the wake of this tragedy, Dormeville felt compelled to help the people of Haiti in any way she could, a call that ultimately led her to pursue a career in pharmacy. “This event significantly affected me and ultimately compelled me to search for a means to … aid in … Haiti’s recovery,” Dormeville, a 2018 PharmD candidate from the South Carolina College of Pharmacy, told Pharmacy Times.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024